Poland's Biotts raises $6.33M pre-IPO, eyes 2027 Warsaw debut
What's the deal? Polish biotech BiottsDealroom has a profile for this one. Try Dealroom → has raised US$6.25M in a pre-IPO round from private investors and family offices, the company said. Investor Mariusz Ksiazek led the round, and Biotts plans to debut on the Warsaw Stock ExchangeDealroom has a profile for this one. Try Dealroom →'s main market in 2027.
What's the endgame? Biotts develops needle-free drug delivery through skin and mucous membranes via its patented MTC-Y platform. Its lead project, MTC-INS, is a transdermal insulin built with BiotonDealroom has a profile for this one. Try Dealroom →, and it is also pursuing transdermal and oral versions of semaglutide, used to treat type 2 diabetes and obesity.
Why now? The proceeds will fund further R&D and IPO preparations. The raise lifts Biotts's total financing, including subsidies, to roughly US$15M.
What could go wrong? Recent insulin results are still preclinical. Human trials will be needed to confirm efficacy and safety, and the planned 2027 listing hinges on that technical and clinical progress.
The signal: Ksiazek, who exited SynektikDealroom has a profile for this one. Try Dealroom → in 2025–2026 for more than US$150M, is backing a company that reworks delivery of known drugs rather than developing new molecules. That bet — plus funding from family offices rather than traditional VC — reflects a lower-risk route into biotech ahead of a public debut.
Read more: biznes.pap.pl
Image credit: Generated with Gemini
